-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, MediciNova Announces First Enrollment In NIH-Supported EAP Trial To Assess MN-166 In Advanced ALS Patients

Benzinga·04/09/2025 07:22:07
Listen to the news

This significant milestone marks the beginning of a critical trial aimed at providing access to MN-166 for ALS patients who are not eligible for the ongoing Phase 2/3 COMBAT-ALS trial. The EAP trial, funded by the National Institutes of Health (NIH) - Neurological Disorders and Stroke (NINDS)1-3, will evaluate the safety and efficacy of MN-166 in approximately 200 ALS patients.